Current/ Expected Orderbook/ Pending Orders?

The company did not provide specific figures regarding the current or expected orderbook/pending orders during the call. It was mentioned that some institutional orders are phased and expected to be fulfilled over the next couple of quarters, indicating a pipeline of pending orders. The Institutional Consumer business experienced a softer Q1 but is expected to show healthy growth on an annual basis. Q2 and Q3 are anticipated to be stronger quarters for fulfilling institutional orders. Export orders missed in Q1 due to production downtime are expected to be fulfilled in Q2. Overall, the company

Any current/future new fundraising through debt or equity?

The company is funding its ongoing and upcoming CAPEX projects through a mix of internal accruals and debt. No explicit mention of new equity fundraising in the call transcript. The balance sheet remains healthy with strong liquidity and conservative leverage, providing flexibility for growth initiatives. Future CAPEX plans, including the overseas formulation facility, are expected to be modest initially (around Rs. 15-20 crore) and may expand depending on market acceptance. Management's focus is on disciplined execution of growth initiatives funded primarily through internal resources and man

Future growth expectations in sales/revenue/volumes?

Rossari Biotech expects mid-double-digit revenue growth of around 14%-15% annually over the next 2 years. Export sales are anticipated to make up approximately 27%-28% of overall turnover on an annualized basis. The Institutional Cleaning and Consumer Business vertical is expected to grow healthily on an annual basis, especially in subsequent quarters after Q1. The B2B business is projected to grow at a faster pace over the next 2-3 years once EO availability improves and new capacities attain optimal utilization. Volume growth in exports has been 11% YoY despite temporary disruptions, indicat

Any current/future capex/capital investment/strategic investment?

Ongoing capacity expansion projects across Rossari Biotech, Unitop Chemicals, and Tristar Intermediates progressing in phases. These expansions aim to eliminate capacity constraints, enhance supply chain agility, and strengthen positioning in high-growth sectors. Commissioning of new capacities expected in upcoming quarters, with full operation and optimal utilization anticipated by FY27, delivering 3x-4x asset turns. An overseas formulation facility is being set up in Southeast Asia with an initial CAPEX of around Rs. 15-20 crore to enhance international presence and customer engagement. Inve

IN US

Sale is live|00:00:00left today

Rossari Biotech LtdQ2 FY25Chemicals & Petrochemicals

Rossari Biotech Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹535P/E: 18.8Market Cap: ₹2.8K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Rossari Biotech expects mid-double-digit revenue growth of around 14%-15% annually over the next 2 years.
→Export sales are anticipated to make up approximately 27%-28% of overall turnover on an annualized basis.
→The Institutional Cleaning and Consumer Business vertical is expected to grow healthily on an annual basis, especially in subsequent quarters after Q1.
→The B2B business is projected to grow at a faster pace over the next 2-3 years once EO availability improves and new capacities attain optimal utilization.
→Volume growth in exports has been 11% YoY despite temporary disruptions, indicating robust demand.
→Capacity expansion projects are underway and expected to deliver 3x-4x asset turnover and margin expansion from FY27 onwards.
→The overseas formulation facility in Southeast Asia will support future international growth and stronger customer engagement in the region.

Margin guidance

Category 3

- Rossari Biotech expects mid-double-digit (14%-15%) growth in both revenue and EBITDA over the next 2 years (Page 8). - EBITDA margin excluding losses from the institutional and consumer business was around 16%; newer verticals are expected to turn margin-accretive by FY27 (Page 4, 11). - The Institutional and B2C business losses are expected to reduce substantially this year, with potential to break even at EBITDA level by FY26 or latest FY27 (Page 10, 11). - Capacity expansions will drive 3x-4x asset turns at optimal utilization, supporting margin expansion and scalable profitable growth, especially from FY27 onwards (Pages 3, 4). - Export growth normalized with expected improvement from Q2 onwards, aiding overall revenue growth (Pages 7, 9). - EO supply constraints easing with anticipated full capacity by FY28, supporting production ramp-up and growth (Pages 6, 9). Overall, the company is building a strong foundation aiming for scalable, profitable growth post FY26.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→The company is funding its ongoing and upcoming CAPEX projects through a mix of internal accruals and debt.
→No explicit mention of new equity fundraising in the call transcript.
→The balance sheet remains healthy with strong liquidity and conservative leverage, providing flexibility for growth initiatives.
→Future CAPEX plans, including the overseas formulation facility, are expected to be modest initially (around Rs. 15-20 crore) and may expand depending on market acceptance.
→Management's focus is on disciplined execution of growth initiatives funded primarily through internal resources and manageable debt levels rather than new large-scale fundraising at this stage.

Order book

→The company did not provide specific figures regarding the current or expected orderbook/pending orders during the call.
→It was mentioned that some institutional orders are phased and expected to be fulfilled over the next couple of quarters, indicating a pipeline of pending orders.
→The Institutional Consumer business experienced a softer Q1 but is expected to show healthy growth on an annual basis.
→Q2 and Q3 are anticipated to be stronger quarters for fulfilling institutional orders.
→Export orders missed in Q1 due to production downtime are expected to be fulfilled in Q2.
→Overall, the company is optimistic about good growth and order execution in the near term, viewing short-term softness as exceptional rather than indicative of longer-term trends.

Capex plans

Yes

→Ongoing capacity expansion projects across Rossari Biotech, Unitop Chemicals, and Tristar Intermediates progressing in phases.
→These expansions aim to eliminate capacity constraints, enhance supply chain agility, and strengthen positioning in high-growth sectors.
→Commissioning of new capacities expected in upcoming quarters, with full operation and optimal utilization anticipated by FY27, delivering 3x-4x asset turns.
→An overseas formulation facility is being set up in Southeast Asia with an initial CAPEX of around Rs. 15-20 crore to enhance international presence and customer engagement.
→Investments are funded through a mix of internal accruals and debt.
→CAPEX work impacted production temporarily due to safety protocols but is on track.
→Full benefit of expanded Ethylene Oxide (EO) capacity expected mostly from September-October 2026, with capacity ramp-up continuing over 3-4 years.
→Focus on phased commissioning and strategic investments to drive scalable and profitable growth from FY27 onwards.

How does Rossari Biotech Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Rossari Biotech Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Rossari Biotech Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio